Concurrent CDK4/6 inhibitors and breast RT show similar discontinuation rates to sequential treatment

In 87 matched pairs, CDK4/6 inhibitor discontinuation was 10.3% with concurrent RT versus 9.2% with sequential treatment.

KEY POINTS

  • This retrospective multicenter study from three Chinese institutions evaluated 364 women with node-positive, operable HR-positive/HER2-negative breast cancer receiving postoperative RT and a CDK4/6 inhibitor between January 2019 and December 2024. 115 patients received concurrent treatment and 249 sequential treatment; propensity score matching generated 87 pairs, with a median overall follow-up of 18 months.
  • Concurrent treatment required CDK4/6 inhibitor administration overlapping the radiation course, whereas the sequential strategy involved withholding the drug for at least seven days before RT, throughout RT, and seven days afterward. Agents included abemaciclib, ribociclib, and palbociclib, predominantly abemaciclib. Breast/chest wall and regional nodal RT used 50 Gy in 25 fractions or 40.05 Gy in 15 fractions, with selected tumor-bed boosts.
  • Permanent CDK4/6 inhibitor discontinuation, the primary endpoint, was not significantly different between strategies. Before matching, discontinuation occurred in 10.4% with concurrent treatment versus 8.4% sequentially (p=0.536). After matching, corresponding rates were 10.3% versus 9.2% (p=0.798), while dose reduction occurred in 13.8% versus 20.7% (p=0.229) and drug substitution in 4.6% of both groups.
  • Severe drug eruptions were numerically more frequent with concurrent therapy. Grade ≥3 drug eruption occurred in 5/115 patients (4.3%) versus 1/249 (0.4%) before matching (unadjusted p=0.013), and 4.6% versus 0% after matching (p=0.059). All severe eruptions involved nonirradiated skin, typically presenting as diffuse maculopapular rashes, and required systemic corticosteroids. The signal did not remain statistically significant after the study's multiplicity correction.
  • No statistically significant differences in pulmonary, gastrointestinal, or hematologic toxicity were identified after matching, although numerical differences remained. Symptomatic radiation-induced lung injury occurred in approximately 4.6% versus 1.1% with concurrent versus sequential treatment, while interstitial pneumonia outside the RT field occurred in 4.6% versus 12.6%. Grade ≥3 diarrhea and neutropenia also showed no statistically significant differences; the small event numbers provide limited power to exclude clinically important harm.
  • Initial treatment groups differed in important characteristics: hypofractionated RT was more common with concurrent therapy (65.2% vs 27.3%; p<0.001), as was grade 3 tumor histology (24.3% vs 12.9%; p=0.031). Before matching, concurrent patients also had lower mean ipsilateral lung dose (13.07 vs 14.23 Gy; p<0.001). These dosimetric differences disappeared after propensity matching, but selection bias from unmeasured treatment and patient factors could remain.
  • Interpretation is limited by retrospective allocation, different observation windows for treatment modification, predominance of abemaciclib, and insufficient power for uncommon severe toxicities. No locoregional control, disease-free survival, or overall survival comparison was conducted. Furthermore, absence of a statistically significant difference does not prove equivalence, and the manuscript contains inconsistent p-values for drug eruption in its Results and Discussion; the primary results are used here.

CLINICAL TAKEAWAY

Concurrent CDK4/6 inhibitor administration with postoperative breast and regional nodal irradiation was not associated with more frequent permanent drug discontinuation than sequential treatment in this propensity-matched observational study. These data provide some reassurance about feasibility, but possible severe skin and pulmonary toxicity signals and the absence of prospective comparative evidence support individualized sequencing and close monitoring rather than routine concurrent administration.

SOURCE

International Journal of Radiation Oncology, Biology, Physics

Browse more research Suggest a correction